Evidence map›Paper›PMID 38884042›Full record

ArticleHemaSphere2024

Quantitative analysis of bone marrow fibrosis highlights heterogeneity in myelofibrosis and augments histological assessment: An Insight from a phase II clinical study of zinpentraxin alfa.

Hosuk Ryou, Korsuk Sirinukunwattana, Ruby Wood, Alan Aberdeen, Jens Rittscher, Olga K Weinberg, Robert Hasserjian, Olga Pozdnyakova, Frank Peale, Brian Higgins and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in HemaSphere, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Hosuk RyouNuffield Department of Medicine University of Oxford Oxford UK.
Korsuk SirinukunwattanaGround Truth Labs, Ltd. Oxford UK.
Ruby WoodInstitute of Biomedical Engineering (IBME), Department of Engineering Science University of Oxford Oxford UK.
Alan AberdeenGround Truth Labs, Ltd. Oxford UK.ORCID https://orcid.org/0000-0001-5483-0905
Jens RittscherGround Truth Labs, Ltd. Oxford UK.
Olga K WeinbergDepartment of Pathology University of Texas Southwestern Medical Center Dallas Texas USA.
Robert HasserjianMassachusetts General Hospital Harvard Medical School Boston Massachusetts USA.
Olga PozdnyakovaDepartment of Pathology and Laboratory Medicine University of Pennsylvania Philadelphia Pennsylvania USA.
Frank PealeGenentech, Inc. South San Francisco California USA.
Brian HigginsGenentech, Inc. South San Francisco California USA.
Pontus LundbergF. Hoffmann-La Roche, Ltd. Basel Switzerland.
Kerstin TrunzerF. Hoffmann-La Roche, Ltd. Basel Switzerland.
Claire N HarrisonGuy's & St Thomas' NHS Foundation Trust London UK.
Daniel RoystonNuffield Division of Clinical Laboratory Sciences (NDCLS), Radcliffe Department of Medicine University of Oxford Oxford UK.ORCID 0000-0002-5151-2378

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID38884042
PMCPMC11176199

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.